Nature of the business (Details) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Jan. 31, 2023	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Jan. 04, 2023	Oct. 14, 2021	Oct. 01, 2021
Net loss		$ 4,270,000	$ 11,653,000
Accumulated deficit		120,271,000		$ 116,001,000
Proceeds from sales of equity and debt		155,100,000
Reimbursement expenses received				17,600,000
Securities aggregate price						$ 200,000,000.0
Cash and cash equivalents		44,424,000	$ 42,879,000	$ 20,323,000
Proceeds from issuance of common stock		$ 34,000
Collaboration agreement with AbbVie
Upfront payment	$ 30,000,000.0
Additional upfront payment					$ 30,000,000.0
Collaboration agreement with AbbVie | Maximum
Additional platform access payments	70,000,000.0
Development and commercial sale milestone receivable per target	120,000,000.0
Sales based milestone based on achievement	$ 150,000,000.0
Potentially eligible amount receivable					$ 2,800,000,000
Open Market Sale
Sale of common stock		5,925
Proceeds from issuance of common stock		$ 34,000
Open Market Sale | Maximum
Securities aggregate price							$ 75,000,000.0